Citable filing context
JNJ's research view summarizes recent SEC filing context, starting with management_change from Aug 4, 2026.
| Filed | Item | Context |
|---|---|---|
| Aug 4, 2026 | management_change | Jennifer Taubert will retire as EVP, Worldwide Chairman, Innovative Medicine, effective September 1, 2026, succeeded by Tom Cavanaugh. |
| Jul 29, 2026 | acquisition | Johnson & Johnson completed the $1 billion acquisition of Firefly Bio, Inc. and entered a collaboration with Sail Biomedicines. |
| Jul 28, 2026 | legal_settlement | Johnson & Johnson reached a $5.5 billion settlement to resolve remaining ovarian talc litigation claims. |
| Jul 29, 2026 | Guidance: adjusted_operational_earnings_per_share | not reported to 0.46 |
| Jul 29, 2026 | Guidance: adjusted_operational_earnings_per_share | not reported to 0.08 |
| Jul 15, 2026 | Guidance: adjusted_eps | 11.60 to 11.75 |
| Jul 23, 2026 | mda_quarterly | Johnson & Johnson reported worldwide sales of $25.3 billion for the second quarter of 2026, a 6.6% increase year-over-year, driven by operational growth of 5.6%. For the first half of 2026, sales reached $49.4 billion, up 8.2%. The Innovative Medicine segment remains a primary growth engine, with oncology sales rising 17.3% in the second quarter, led by DARZALEX, CARVYKTI, and the RYBREVANT/LAZCLUZE combination. However, the segment faces significant headwinds from the decline of STELARA, which saw a 55.2% worldwide sales drop due to biosimilar competition. Neuroscience also performed well, with SPRAVATO and CAPLYTA showing strong momentum. The MedTech segment grew 4.5% in the second quarter, supported by electrophysiology and orthopaedics. The company is currently executing a restructuring program for its surgery and orthopaedics franchises, with the latter slated for a planned separation within 18 to 24 months. Financial results were impacted by $0.4 billion in talc-related charges during the second quarter, bringing the total talc reserve to approximately $3.7 billion. The company maintains a strong liquidity position with $20.8 billion in cash and marketable securities and has secured a new $12.5 billion credit facility to support general corporate needs and commercial paper. |
| Apr 22, 2026 | mda_quarterly | Johnson & Johnson repurchased an aggregate of 16,834,220 shares of its common stock during the fiscal first quarter of 2026, spanning from December 29, 2025, to March 29, 2026. These shares were acquired through open-market transactions at an average price of $239.26 per share. The repurchases were conducted as part of a systematic plan to fulfill the Company’s compensation program requirements, and this total included shares from stock-for-stock option exercises settled within the quarter. No shares were purchased under any publicly announced repurchase plans or programs, and no remaining authorization existed under such programs. |
Source: SEC EDGAR filing text and events; period Aug 4, 2026; filed Aug 4, 2026.
JNJ company research is available with Aerarium Pro (CAD $10/mo). The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay free. Already a subscriber? Sign in to pick up where you left off.